RT期刊文章SR电子T1膳食治疗类似中风发作的药物不良反应(P04.162)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P04.162 OP P04.162 VO 78首页是1补充A1 Hisatomo Kowa A1 Tohko Miyawaki A1吴克群Sekiguchi A1 Fumio神田A1 Tatsushi户田拓夫年2012 UL //www.ez-admanager.com/content/78/1_Supplement/P04.162.abstract AB目的:测试是否药物不良反应、自由基的清道夫,能防止中风病灶扩散看见病人。背景类似中风的米拉引起很多症状包括轻偏瘫,改变意识、偏盲、癫痫和剧烈的头痛。重复类似中风发作可以逐步损害大脑,导致脑萎缩,导致视力丧失、运动和痴呆的问题。但是,没有治疗对预防类似中风发作已经建立。药物不良反应是一个神经剂用于帮助神经系统急性脑缺血后恢复的目的。它作为一种强有力的抗氧化剂,大力进行清除自由基,防止氧化应激和神经细胞凋亡。设计/方法:三个米拉mtDNA突变患者np 3243一直在评估临床症状,而图像顺序。六个类似中风发作观察在这些情况下,四个精氨酸处理,抗癫痫药物。药物不良反应是应用于两集连续14天期间除了常规治疗。结果:皮质病变遭受类似中风事件显示在两个月后集中严重萎缩的药物治疗。大多数症状引起的病态的皮层仍然很长一段时间。 By contrast, when treated with edaravone within one week after onset of episode, cortical atrophy was avoided, and cortical functions were recovered very well. Controls of epilepsy was relatively easier in episodes treated with edaravone compared to edaravone unused attacks.Conclusions: Our experience suggests that edaravone could prevent brain atrophy of lesions suffering from stroke-like episodes. Clinical trial in large-scale is necessary to conclude the efficiency of edaravone on stroke-like episodes of MELAS.Disclosure: Dr. Kowa has nothing to disclose. Dr. Miyawaki has nothing to disclose. Dr. Sekiguchi has nothing to disclose. Dr. Kanda has nothing to disclose. Dr. Miyawaki has nothing to disclose.Wednesday, April 25 2012, 07:30 am-12:00 pm